|
||
|
SEARCH BY KEYWORD
|
Category: AllTea LeavesJuly 27, 2006
In my reading of the tea leaves over what's coming in the health reform debate, I am worried about what I see.
Three examples:
We are on a sprint to save the private health sector, and we have barely a moment to waste in helping the competitive health care economy to put down roots and give Americans real choice and control over their health care. Join with us. Grace-Marie Turner RECENT NEWS ARTICLES AND STUDIES:
MARKET PRINCIPLES: THE RIGHT PRESCRIPTION FOR MEDICAID Florida's Medicaid Reform Plan offers a "new vision of Medicaid [that] respects and trusts the participants by allowing them to make decisions about their health care based on their personal needs, instead of having bureaucrats arbitrarily do it for them based on contracts and directives," writes Governor Jeb Bush in an article for Stanford Law & Policy Review. He provides a comprehensive description of his state's new Medicaid waiver plan that includes disease prevention and personal responsibility. "We are reinventing the incomprehensible maze that is Medicaid today into a patient-centric system that enhances the quality of life for Floridians who rely on Medicaid services, rewards healthy lifestyle decisions, and saves millions of dollars."
The Pacific Research Institute has released a new book on free market health care reform featuring chapters written by seven leading scholars. "The purpose of this primer is to educate state policymakers, legislators, and consumers about where we've gone wrong with health care and how we can fix it," said Editor John Graham. Topics covered include Medicaid, health insurance, physician quality assurance, prescription piracy, pharmaceutical costs, hospital certificate-of-need laws, and malpractice liability. "States have significant authority to make positive changes independent of what the federal government does," said Graham. "Although every state faces a different situation, the policies outlined in this book can serve as a blueprint for reform."
Increased state-level regulation of health insurance leads to higher health insurance premiums, writes Michael New of The Heritage Foundation. Using data from 2005 and 2006, he compares the cost of health insurance plans across several states and focuses on four sets of state regulations: mandated benefits, health plan liability, direct-access-to-specialists, and provider due process. New finds that, over the two years, direct access to specialists can increase premiums by $31.15, while liability laws increase premiums by $21.84. Additionally, "states with more than 26 mandated benefits have higher premiums than states with 26 or fewer benefits." This is a follow-up to a study published by Heritage and written by Grace-Marie Turner of Galen in 1998 entitled: "Uninsured Rates Rise Dramatically in States With Strictest Health Insurance Regulations."
The Stockholm Network, based in London, and the Center for Medicine in the Public Interest, based in New York, have jointly published a book exploring the "frightening and dangerous growth in prescription drug counterfeiting." Editor Peter Pitts of CMPI has gathered "some of the world's leading experts" to provide "creative, timely and most importantly, practical and functional solutions to this crucial global health crisis."
The use of cost-effectiveness data by Britain's National Institute for Health and Clinical Excellence (NICE) "is a flawed concept whose implementation has proven problematic for patients, health professionals, and pharmaceutical innovation," writes Heinz Redwood, Ph.D., a British health policy expert and author. Decisions based upon cost-effectiveness data have resulted in delayed or limited access to new medicines for patients with chronic diseases like multiple sclerosis, chronic myeloid leukemia, macular degeneration, and osteoporosis. "The value of pharmaceutical innovations often cannot be captured in conventional accounting calculations," concludes Redwood. "Cost-effectiveness decisions refer either to the 'average' patient or to the average of a defined segment of a patient population ?Yet innovation in prescription medicines is moving increasingly towards the needs of the individual, nonaverage patient, particularly in life threatening diseases." UPCOMING EVENTS: Medical Tourism: Affordable Alternative or Compromised Care Preparing for the National Provider Identifier: What it Means for the Industry Crisis of Abundance: Arnold Kling Health Policy Matters is a weekly newsletter containing summaries of timely and informative studies and articles on free-market health reform. It features research and writings by participants in the Health Policy Consensus Group, articles of interest from the health policy world, and announcements of coming events. Health Policy Matters is published by the Galen Institute, a not-for-profit public policy organization specializing in information and education on health policy. For more information about the newsletter and our organization, please visit our website at http://www.galen.org/. If you wish to subscribe to this free weekly newsletter, update your address, or be removed from our list, please send an e-mail message to galen@galen.org. The views expressed in this newsletter are the opinions of the authors and do not necessarily reflect the views of the Galen Institute or its directors. CommentsNo comments Add Comment |
|